| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-02-15 | Aranesp® (darbepoetin alfa) | anemic patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) | 3 | Amgen (USA - CA) | Cancer - Oncology |
| 2016-02-14 | JHL1101 (biosimilar version of rituximab) | rheumatoid arthritis | 3 | JHL Biotech (Taiwan) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-02-13 | liraglutide | NASH (non-alcoholic steatohepatitis) | 2 | Novo Nordisk (Denmark) | Hepatic diseases - Liver diseases |
| 2016-02-12 | pembrolizumab (MK-3475) | Hodgkin lymphoma | 3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2016-02-12 | CLBS03 | diabetes | 2 | Caladrius Biosciences (USA - CA) | Metabolic diseases |
| 2016-02-11 | elafibranor - GFT505 | NASH (non-alcoholic steatohepatitis) | 2b | Genfit (France) | Metabolic diseases - Liver diseases |
| 2016-02-11 | ruxolitinib and capecitabine | metastatic pancreatic cancer | 3 | Incyte (USA - DE) | Cancer - Oncology |
| 2016-02-10 | ALLN-177 | secondary hyperoxaluria | 2 | Allena Pharmaceuticals (USA - MA) | Kidney diseases - Renal diseases |
| 2016-02-10 | Accurins™ | preclinical | Bind Therapeutics (USA - MA) | Cancer - Oncology | |
| 2016-02-10 | elagolix | endometriosis | 3 | Abbvie (USA - IL) Neurocrine Biosciences (USA - CA) | Women health |
| 2016-02-10 | IMMray™systemic lupus erythematosus biomarker signatures | systemic lupus erythematosus (SLE) | Immunovia (Sweden) Lund University (Sweden) | Autoimmune diseases | |
| 2016-02-10 | HTL9936 | Alzheimer’s disease and other diseases associated with dementia and cognitive impairment | 1b | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) | Neurodegenerative diseases |
| 2016-02-09 | CAR-T cell therapy modified using the Sleeping Beauty system | advanced lymphoid malignancies | 1 | Ziopharm Oncology (USA - MA) | Cancer - Oncology |
| 2016-02-09 | remimazolam | general anesthesia | 3 | Paion (Germany) | CNS diseases |
| 2016-02-09 | 4Kscore® Test | prostate cancer | Opko Health (USA - Fl) | Cancer - Oncology | |
| 2016-02-08 | PM1183 plus doxorubicin | ovarian cancer | 3 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-02-07 | Mast Cell Connect patient registry | mastocytosis | Blueprint Medicines (USA - MA) PatientCrossroads (USA - CA) | Rare diseases - Hematological diseases | |
| 2016-02-05 | Blincyto® (blinatumomab) | Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | 3 | Amgen (USA - CA) | Cancer - Oncology |
| 2016-02-05 | AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor, AG-221 (enasidenib) and subcutaneous azacitidine | acute myeloid leukemia (AML) | 1-2 | Celgene (USA - NJ) | Cancer - Oncology |
| 2016-02-04 | MYK-461 | hypertrophic cardiomyopathy | preclinical | Myokardia (USA - CA) | Cardiovascular diseases |
